Airway inflammation in mild cystic fibrosis

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

William G. Flight, Jonathan Shaw, Susan Johnson, A

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

Katarine Egressy, Michaelene Jansen, Keith C. Meyer

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Regional ventilation in cystic fibrosis measured by electrical impedance tomography Zhanqi Zhao, Rainald Fischer, Inéz Frerichs, Ullrich Müller-Lisse,

Raphaël Chiron, Y. Yaël Grumbach, Nga V. T

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis Mireen Friedrich-Rust, Nina Schlueter, Christina Smaczny, Olaf.

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Amanda L. Brennan, Khin M. Gyi, David M

The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited Abaigeal D. Jackson, Leslie Daly,

Fiona K. Dunlevy, S. Lorraine Martin, Francine de Courcey, J

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis Catriona Kelly, Mark T. Williams, J. Stuart.

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Evaluation of salt supplementation in CF infants

Vitamin A and lung function in CF

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects Warren Lenney, Frank Edenborough,

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Cytokine gene polymorphisms and severity of CF lung disease

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic Amanda L. Griffiths, Danielle F. Wurzel,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Soluble inflammation markers in nasal lavage from CF patients and healthy controls Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

N Dauletbaev, K Viel, R Buhl, T.O.F Wagner, J Bargon

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Robert P. Thomen, Laura L. Walkup, David J. Roach, Zackary I

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Presentation transcript:

Airway inflammation in mild cystic fibrosis Jonas Eckrich, Ulrich M. Zissler, Friederike Serve, Patricia Leutz, Christina Smaczny, Sabina Schmitt-Grohé, Daniela Fussbroich, Ralf Schubert, Stefan Zielen, Olaf Eickmeier Journal of Cystic Fibrosis Volume 16, Issue 1, Pages 107-115 (January 2017) DOI: 10.1016/j.jcf.2016.05.016 Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Lung function measurements of CF patients and controls. Lung function data for (a) FVC, (b) FEV1, (c) MEF25, and (d) RV/TLC are shown as % predicted with the bar marking the median. The non-parametric Mann–Whitney test was used for comparisons between CF patients with and without SAD and healthy controls. Differences between CF groups and controls: *=p<0.05, **=p<0.01, ***=p<0.001. Journal of Cystic Fibrosis 2017 16, 107-115DOI: (10.1016/j.jcf.2016.05.016) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 mRNA expression levels for selected cytokines/chemokines in sputum of CF patients and controls. Data for (a) IL-1ß, (b) IL-6, (c) IL-8, and (d) TNF-α are shown as relative gene expression using comparative threshold cycle (2−ΔΔCt) method with the bar marking the median. The non-parametric Mann–Whitney test was used for comparisons between CF patients with and without SAD and healthy controls. Differences between CF groups and controls: *=p<0.05, **=p<0.01, ***=p<0.001. Journal of Cystic Fibrosis 2017 16, 107-115DOI: (10.1016/j.jcf.2016.05.016) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Protein levels by CBA for selected cytokines/chemokines in sputum of CF patients and controls. Data for (a) IL-1ß, (b) IL-6, and (c) IL-8 are shown as median (range). The non-parametric Mann–Whitney test was used for comparisons between CF patients without and with SAD and healthy control subjects. Differences between CF groups and controls: *=p<0.05, **=p<0.01, ***=p<0.001. Journal of Cystic Fibrosis 2017 16, 107-115DOI: (10.1016/j.jcf.2016.05.016) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions